Biogen Idec (BIIB) Could Be One To Watch On ImClone Bid

Watch Biogen Idec Inc. (Nasdaq: BIIB) on news that Bristol-Myers Squibb Co. (NYSE: BMY) offered to acquire ImClone (Nasdaq: IMCL) at a hefty premium of $60 per share.

Carl Icahn is a shareholder of BIIB and IMCL.

You May Also Be Interested In

• Mavis acquires Pep Boys from Icahn Enterprises for $700M
• SpaceX attempted to acquire AI coding startup Cognition - Bloomberg
• Holcim said to acquire part of James Hardie's EU business